Myriad Genetics, a leader in genetic testing and precision medicine, has recently announced an exciting update to their MyRisk® with RiskScore® Breast Cancer Risk Assessment. This comprehensive risk model now includes breast density as a key factor, along with personal/family history and genetic markers. By incorporating this additional information, patients and healthcare providers can gain a more thorough understanding of their five-year and lifetime risk for breast cancer.
Breast density plays a crucial role in the screening and diagnosis of breast cancer. Higher-density tissue can make it more challenging to detect abnormalities or cancerous masses during routine screenings, often requiring further imaging tests. With the integration of breast density information into MyRisk with RiskScore, healthcare providers will be better equipped to offer personalized care and identify breast cancer at its earliest stages when treatment outcomes are most favorable.
The inclusion of breast density in this risk assessment tool has been met with enthusiasm by industry professionals like John Simon, CEO of SimonMed. He emphasizes that higher breast density is associated with an increased risk of developing breast cancer. By integrating breast density into their risk assessment tool, Myriad Genetics aims to save lives through